• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非诺贝特单药治疗致甲状腺功能减退患者横纹肌溶解症:1例罕见病例报告及文献复习

Fenofibrate monotherapy-induced rhabdomyolysis in a patient with hypothyroidism: A rare case report and literature review.

作者信息

Wang Dawei, Wang Yanqiu

机构信息

Department of Neurosurgery, the second affiliated hospital of Bengbu medical college, Bengbu Department of Endocrinology, Benxi Central Hospital, Liaoning, People's Republic of China.

出版信息

Medicine (Baltimore). 2018 Apr;97(14):e0318. doi: 10.1097/MD.0000000000010318.

DOI:10.1097/MD.0000000000010318
PMID:29620657
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5902300/
Abstract

RATIONALE

Fenofibrate is a fibric acid derivative indicated for use in hypertriglyceridemia and mixed dyslipidemia treatment among adults. Rhabdomyolysis is a syndrome characterized by muscle necrosis and the release of intracellular muscle contents into the systemic circulation, which is the most serious and fatal side effect of fenofibrate. The objective of this paper is to discuss fatal side effect of fenofibrate and keep safe medication.

PATIENT CONCERNS

A patient with hypothyroidism who presented with rhabdomyolysis during fenofibrate monotherapy for hypertriglyceridemia was reported.

DIAGNOSES

Fenofibrate Monotherapy Induced Rhabdomyolysis.

INTERVENTIONS

Fenofibrate was stopped. Adequate fluid resuscitation, mannitol diuresis, myocardium protection, hepatoprotection and urine alkalinization with sodium bicarbonate were performed.

OUTCOMES

Blood tests were normal and the patient was good and discharged 2 weeks later.

LESSONS

13 cases associated with fenofibrate monotherapy-induced rhabdomyolysis were reviewed, which had been published in the English literature. The severity of fenofibrate muscle toxicity may be the result of the combination of two rhabdomyolysis enhancers, such as hypothyroidism and female gender. To avoid it, strict clinical and laboratory monitoring should be maintained, particularly hypothyroidism. Patients should be informed of possible potentially irreversible effects after taking fibrates.

摘要

理论依据

非诺贝特是一种纤维酸衍生物,适用于治疗成人高甘油三酯血症和混合性血脂异常。横纹肌溶解症是一种以肌肉坏死和细胞内肌肉成分释放进入体循环为特征的综合征,是非诺贝特最严重和致命的副作用。本文旨在探讨非诺贝特的致命副作用并确保安全用药。

患者情况

报告了一名甲状腺功能减退患者,在接受非诺贝特单药治疗高甘油三酯血症期间出现横纹肌溶解症。

诊断

非诺贝特单药治疗引起的横纹肌溶解症。

干预措施

停用非诺贝特。进行了充分的液体复苏、甘露醇利尿、心肌保护、肝脏保护以及用碳酸氢钠碱化尿液。

结果

血液检查正常,患者情况良好,2周后出院。

经验教训

回顾了英文文献中发表的13例与非诺贝特单药治疗引起的横纹肌溶解症相关的病例。非诺贝特肌肉毒性的严重程度可能是两种横纹肌溶解症增强因素(如甲状腺功能减退和女性性别)共同作用的结果。为避免这种情况,应进行严格的临床和实验室监测,尤其是甲状腺功能减退方面。应告知患者服用贝特类药物后可能出现的潜在不可逆影响。

相似文献

1
Fenofibrate monotherapy-induced rhabdomyolysis in a patient with hypothyroidism: A rare case report and literature review.非诺贝特单药治疗致甲状腺功能减退患者横纹肌溶解症:1例罕见病例报告及文献复习
Medicine (Baltimore). 2018 Apr;97(14):e0318. doi: 10.1097/MD.0000000000010318.
2
Fenofibrate-induced rhabdomyolysis in a patient with chronic kidney disease: an unusual presenting feature of hypothyroidism.非诺贝特诱发的慢性肾病患者横纹肌溶解症:甲状腺功能减退症的一种不寻常表现特征
Arq Bras Endocrinol Metabol. 2009 Apr;53(3):383-6. doi: 10.1590/s0004-27302009000300015.
3
Fenofibrate monotherapy-induced rhabdomyolysis in a patient with post-pancreatitis diabetes mellitus: A rare case report and a review of the literature.非诺贝特单药治疗致胰腺炎后糖尿病患者横纹肌溶解症:1例罕见病例报告及文献复习
Medicine (Baltimore). 2020 May 22;99(21):e20390. doi: 10.1097/MD.0000000000020390.
4
Hypothyroidism is a predisposing factor for fenofibrate-induced rhabdomyolysis--patient report and literature review.甲状腺功能减退是非诺贝特诱导的横纹肌溶解的一个诱发因素——病例报告及文献综述。
Drug Metabol Drug Interact. 2007;22(4):279-83. doi: 10.1515/dmdi.2007.22.4.279.
5
A case of rhabdomyolysis complicated with acute renal failure after resumption of fenofibrate therapy: a first report.恢复非诺贝特治疗后肌红蛋白尿合并急性肾衰竭 1 例:首次报道。
Indian J Pharmacol. 2013 May-Jun;45(3):305-6. doi: 10.4103/0253-7613.111912.
6
A case of rhabdomyolysis induced acute renal failure secondary to statin-fibrate-derivative combination and occult hypothyroidism.一例因他汀类药物与贝特类衍生物联用及隐匿性甲状腺功能减退继发横纹肌溶解症所致急性肾衰竭。
Clin Nephrol. 2005 Nov;64(5):391-3. doi: 10.5414/cnp64391.
7
Fenofibrate-induced rhabdomyolysis in two dialysis patients with hypothyroidism.非诺贝特致两名甲状腺功能减退透析患者横纹肌溶解症
Nephrol Dial Transplant. 1999 Apr;14(4):1047-8. doi: 10.1093/ndt/14.4.1047.
8
Fenofibrate-induced rhabdomyolysis in a patient with stage 4 chronic renal failure due to diabetes mellitus.非诺贝特诱发的横纹肌溶解症在一名因糖尿病导致慢性肾衰竭4期的患者中发生。
J Pak Med Assoc. 2012 Aug;62(8):849-51.
9
[Rhabdomyolysis induced by fenofibrate monotherapy].[非诺贝特单药治疗引起的横纹肌溶解症]
Rev Med Interne. 2006 Jul;27(7):573-4. doi: 10.1016/j.revmed.2006.02.013. Epub 2006 May 3.
10
Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients.两例患者在同时服用他汀类药物后,因非诺贝特诱发严重横纹肌溶解导致急性肾衰竭。
Intern Med. 2008;47(11):1017-9. doi: 10.2169/internalmedicine.47.0939. Epub 2008 Jun 2.

引用本文的文献

1
Pharmacokinetics and Safety of Pemafibrate in Patients with both Dyslipidemia and Severe Renal Impairment: A Phase 4 Study.Pemafibrate在血脂异常合并严重肾功能损害患者中的药代动力学和安全性:一项4期研究。
J Atheroscler Thromb. 2025 Feb 1;32(2):210-225. doi: 10.5551/jat.64887. Epub 2024 Sep 5.
2
Clinical and pathological aspects of toxic myopathies.中毒性肌病的临床与病理特征
J Neurol. 2024 Sep;271(9):5722-5745. doi: 10.1007/s00415-024-12522-x. Epub 2024 Jun 21.
3
Valerenic acid attenuates pathological myocardial hypertrophy by promoting the utilization of multiple substrates in the mitochondrial energy metabolism.缬草烯酸通过促进线粒体能量代谢中多种底物的利用来减轻病理性心肌肥大。
J Adv Res. 2025 Feb;68:241-256. doi: 10.1016/j.jare.2024.02.008. Epub 2024 Feb 18.
4
Can coenzyme Q10 alleviate the toxic effect of fenofibrate on skeletal muscle?辅酶 Q10 能否减轻非诺贝特对骨骼肌的毒性作用?
Histochem Cell Biol. 2023 Aug;160(2):147-158. doi: 10.1007/s00418-023-02205-5. Epub 2023 Jun 4.
5
Role of branched-chain amino acid metabolism in the pathogenesis of obesity and type 2 diabetes-related metabolic disturbances BCAA metabolism in type 2 diabetes.支链氨基酸代谢在肥胖和 2 型糖尿病相关代谢紊乱发病机制中的作用 2 型糖尿病中的支链氨基酸代谢。
Nutr Diabetes. 2022 Aug 5;12(1):35. doi: 10.1038/s41387-022-00213-3.
6
A Narrative Review of Statin-Induced Rhabdomyolysis: Molecular Mechanism, Risk Factors, and Management.他汀类药物诱导的横纹肌溶解症的叙述性综述:分子机制、危险因素及管理
Drug Healthc Patient Saf. 2021 Nov 8;13:211-219. doi: 10.2147/DHPS.S333738. eCollection 2021.
7
The role of peroxisome proliferator-activated receptors in healthy and diseased eyes.过氧化物酶体增殖物激活受体在健康和患病眼睛中的作用。
Exp Eye Res. 2021 Jul;208:108617. doi: 10.1016/j.exer.2021.108617. Epub 2021 May 16.
8
Effects of low and high doses of fenofibrate on protein, amino acid, and energy metabolism in rat.低、高剂量非诺贝特对大鼠蛋白质、氨基酸和能量代谢的影响。
Int J Exp Pathol. 2020 Oct;101(5):171-182. doi: 10.1111/iep.12368. Epub 2020 Sep 1.
9
Severe proximal myopathy secondary to Hashimoto's thyroiditis.桥本甲状腺炎继发的严重近端肌病。
BMJ Case Rep. 2019 Jul 27;12(7):e230427. doi: 10.1136/bcr-2019-230427.

本文引用的文献

1
Fenofibrate-induced rhabdomyolysis in a patient with stage 4 chronic renal failure due to diabetes mellitus.非诺贝特诱发的横纹肌溶解症在一名因糖尿病导致慢性肾衰竭4期的患者中发生。
J Pak Med Assoc. 2012 Aug;62(8):849-51.
2
A case of rhabdomyolysis complicated with acute renal failure after resumption of fenofibrate therapy: a first report.恢复非诺贝特治疗后肌红蛋白尿合并急性肾衰竭 1 例:首次报道。
Indian J Pharmacol. 2013 May-Jun;45(3):305-6. doi: 10.4103/0253-7613.111912.
3
Rhabdomyolysis-induced acute renal failure following fenofibrate therapy: a case report and literature review.非诺贝特治疗后横纹肌溶解症诱发的急性肾衰竭:一例报告及文献综述
Case Rep Med. 2010;2010. doi: 10.1155/2010/537818. Epub 2010 Jul 25.
4
Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report.与贝特类药物治疗相关的横纹肌溶解症:76 例已发表病例的回顾分析及 1 例新病例报告。
Eur J Clin Pharmacol. 2009 Dec;65(12):1169-74. doi: 10.1007/s00228-009-0723-7. Epub 2009 Sep 16.
5
Fenofibrate-induced rhabdomyolysis in a patient with chronic kidney disease: an unusual presenting feature of hypothyroidism.非诺贝特诱发的慢性肾病患者横纹肌溶解症:甲状腺功能减退症的一种不寻常表现特征
Arq Bras Endocrinol Metabol. 2009 Apr;53(3):383-6. doi: 10.1590/s0004-27302009000300015.
6
Fenofibrate monotherapy-induced rhabdomyolysis in a patient with type-2 diabetes.非诺贝特单药治疗诱发2型糖尿病患者横纹肌溶解症
Indian J Med Sci. 2008 Nov;62(11):458-9.
7
A case of rhabdomyolysis and thromboembolic event secondary to fibrate monotherapy.
Acta Cardiol. 2008 Aug;63(4):515-7. doi: 10.2143/AC.63.4.2033052.
8
Acute renal failure secondary to fenofibrate monotherapy-induced rhabdomyolysis.非诺贝特单药治疗引起横纹肌溶解继发急性肾衰竭。
Ren Fail. 2007;29(7):927-30. doi: 10.1080/08860220701573640.
9
Rhabdomyolysis disclosing hypothyroidism.横纹肌溶解症揭示甲状腺功能减退症。
Eur J Intern Med. 2006 May;17(3):220. doi: 10.1016/j.ejim.2005.11.004.
10
Fenofibrate-induced myopathy.
Neurol India. 2004 Jun;52(2):268-9.